ALLMedicine™ Prostatic Hyperplasia Center

Jan 11th, 2022 - Prostate cancer (PCa) is a genetically heterogeneous disease with highly molecular aberrations. It has been revealed that a newly discovered class of non-coding RNAs called circular RNAs (circRNAs) play key roles in dictating tumor behaviors and p...

Jan 4th, 2022 - Bipolar transurethral resection of the prostate (TURP) is an effective and safe alternative to monopolar TURP. The aim of this study was to investigate the influence of resected prostate weight on the clinical outcome improvement after bipolar TUR...

Jan 1st, 2022 - Extracellular vesicles (EVs) contain various types of molecules including micro-RNAs, so isolating EVs can be an effective way to analyze and diagnose diseases. A lot of micro-RNAs have been known in relation to prostate cancer (PCa), and we evalu...

Dec 30th, 2021 - Men are more likely to develop benign prostatic hyperplasia (BPH) and gout as they age. However, the role of alpha-1-adrenergic antagonists, the medication for BPH, in the development of gout is uncertain. To investigate the effect of alpha-1-adre...

Dec 24th, 2021 - The objective of this study was to compare the efficacy and safety of 10 different surgical treatments for benign prostatic hyperplasia (BPH) with volume >60 mL. A systematic literature review and network meta-analysis of randomized controlled tri...

Aug 14th, 2021 - Benign prostatic hyperplasia (BPH) is a histologic diagnosis describing proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and severity of lower urinary tract symptoms (LUTS) in aging men are p...

Jul 24th, 2020 - The AUA Guideline panel provides evidence-based recommendations for the surgical management of male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The Panel amended the Guideline in 2020 to reflect additional ...

May 7th, 2019 - Male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is common in men and can have negative effects on quality of life (QoL). It is the hope that this Guideline becomes a reference for effective evidence-based s...

Mar 12th, 2016 - In 2014, the Korean Urological Association organized the Benign Prostatic Hyperplasia Guideline Developing Committee composed of experts in the field of benign prostatic hyperplasia (BPH) with the participation of the Korean Academy of Family Medi...

Sep 1st, 2021 - The American Urological Association (AUA) has updated its guidelines on managing male lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH). The updates, the first since 2010, were summarized in the Journal of Urolog...

Jul 13th, 2021 - For patients with benign prostatic hyperplasia (BPH), there are several options when to comes to surgical treatment. A comparison of real-world outcomes reveals significant differences in postprocedural complication and re-treatment rates. The res...

Feb 25th, 2021 - NEW YORK (Reuters Health) - Photoselective vaporization of the prostate can provide relief from refractory lower-urinary-tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH) in prostate cancer patients managed by active surveill...

Feb 9th, 2021 - Certain drugs currently used to treat benign prostatic hyperplasia (BPH) may provide neuroprotection and delay or prevent the onset of Parkinson's disease, new research suggests. Treatment of BPH with terazosin (Hytrin), doxazosin (Cardura), or al...

Jan 12th, 2021 - Benign prostatic hyperplasia (BPH) is present in as many as 60% of men in their 60s and 90% of men older than 70 years. BPH describes nonmalignant prostate tissue growth and commonly causes lower urinary tract symptoms (LUTS). Not all men with BPH...